Science Center - CHISHIKI

Sosei Heptares group welcomes you to CHISHIKI, the destination for updates on our progress in the world of GPCRs. CHISHIKI is the Japanese word for “knowledge.” CHISHIKI is our online voice for communicating the scientific progress of our research and development activities, together with our broader contributions to the area of GPCRs.

RSS Feed


Drug Discovery

Sosei Heptares actively participates in the next European Training Network ONCORNET 2.0

By Chris de Graaf | Jun 5, 2019

The EU has awarded 4 million Euros for ITN research programme ONCORNET2.0, which aims to understand and target two oncogenic G protein-coupled receptors (GPCRs) highly expressed in multiple tumors. The consortium will develop new strategies for chemokine receptor modulation and investigate their effects on oncogenic responses, to yield key new knowledge and potential leads for drug development.

READ MORE...

Development

QVM149, a potential new inhaled combination treatment, is superior to high-dose salmeterol/fluticasone propionate in improving lung function in patients with asthma (ATS 2019)

By Novartis | May 22, 2019

Novartis presented new clinical data from its Phase II study with QVM149, a potential new inhaled combination treatment for asthma, assessing the bronchodilator effect and safety of two doses of QVM149 compared to a fixed dose combination of salmeterol/fluticasone in adult patients with asthma.

READ MORE...

Development

QVM149, a potential new inhaled combination treatment, demonstrates improvements in lung function in patients with asthma irrespective of time of dosing

By Novartis | May 22, 2019

Novartis presented new clinical data from its Phase II study with QVM149, a potential new inhaled combination treatment for asthma, assessing the bronchodilator effects of once daily QVM149 following morning or evening dosing for 14 Days compared to placebo in adult patients with asthma.

READ MORE...

Platform Technology

Molecular basis for high affinity agonist binding in GPCRs

By Andrew Doré | May 9, 2019

Dr Andrew Doré, Director - Head of Crystallography at Sosei Heptares, recently published a paper in Science, titled "Molecular basis for high affinity agonist binding in GPCRs",  alongside fellow co-authors from the MRC Laboratory of Molecular Biology – Tony Warne, Patricia Edwards, Andrew Leslie and Chris Tate (Co-Founder, Heptares Therapeutics).

READ MORE...

Platform Technology

Aminergic GPCR–Ligand Interactions: A Chemical and Structural Map of Receptor Mutation Data

By Chris De Graaf | May 7, 2019

Dr. Chris De Graaf, Head of Computational Chemistry at Sosei Heptares, recently published a paper in the renowned Journal of Medicinal Chemistry, titled “Aminergic GPCR–Ligand Interactions: A Chemical and Structural Map of Receptor Mutation Data” alongside fellow co-authors from VU University Amsterdam, Polish Academy of Sciences and University of Copenhagen.

READ MORE...

Platform Technology

Application of structure-based drug discovery to G Protein-Coupled Receptors

By Rob Cooke | May 2, 2019

We recently attended the 30th Symposium on Medical Chemistry in Eastern England on 2 May 2019 in Hatfield, United Kingdom and presented on the application of structure-based drug discovery to GPCRs. 

READ MORE...

Development

AZD4635, a novel oral adenosine A2A receptor antagonist, shows clinical activity as a monotherapy or in combination with Imfinzi® (durvalumab) in patients with advanced solid tumors (AACR 2019)

By AstraZeneca | Apr 14, 2019

AstraZeneca presented new clinical data from its Phase 1a study with AZD4635, a next-generation immuno-oncology candidate, as a single agent and in combination with the PD-L1 antibody durvalumab, in patients with advanced solid tumors, at the 2019 American Association for Cancer Research (AACR) Annual Meeting in Atlanta, USA (29 March to 3 April 2019).

READ MORE...

Development

AZD4635, a novel adenosine A2A receptor antagonist, restores anti-tumor activity by preventing adenosine-mediated suppression of immune cells (AACR 2019)

By AstraZeneca | Apr 14, 2019

AstraZeneca presented new data from preclinical studies with AZD4635, a next-generation immuno-oncology candidate, demonstrating its ability to restore the anti-tumor activity of dendritic cells (DCs) by preventing their adenosine-mediated immunosuppression. The new data were presented in a poster at the 2019 American Association for Cancer Research (AACR) Annual Meeting in Atlanta, USA (29 March to 3 April 2019).

READ MORE...

Development

Fibromyalgia: an urgent need for a harmonised, global and patient-centric regulatory guidance for developing medications for the treatment of pain and associated symptoms

By Dr Nico Merante | Apr 11, 2019

Dr Nico Merante, VP Development of Sosei Heptares recently published an article in Pain Medicine Journal, “Fibromyalgia: an urgent need for a harmonised, global and patient-centric regulatory guidance for developing medications for the treatment of pain and associated symptoms".

READ MORE...

Platform Technology

Enabling FBDD for GPCRs with Protein Engineering and Biophysics

By Rob Cooke | Apr 5, 2019

We recently attended the 7th RSC-BMCS Fragment-based Drug Discovery meeting on March 24–26th in Cambridge, United Kingdom and presented on fragment-based drug discovery (FBDD) for GPCRs with protein engineering and biophysics.

READ MORE...

Development

Basal forebrain volumes predict circuit specific functional sensitivity to the muscarinic M1 receptor antagonist biperiden on cognition

By Geor Bakker, PhD, Pradeep Nathan PhD, Alex Godwood MSc. | Apr 3, 2019

We recently attended the Alzheimer’s & Parkinson’s Diseases (ADPD) Conference on 29th March in Lisbon, Portugal where we presented data in the session “Huntington’s and Other Neurodegenerative Diseases: Imaging, Biomarkers, Diagnostics”. In a collaboration led by Sosei Heptares, with the Amsterdam University Medical Centres and Maastricht University, we presented our novel findings in a poster showing that the basal forebrain nuclei volumes can sensitively predict circuitry specific effects of M1 receptor antagonist biperiden on cognition. This work forms an important part of the goals of the Neuroscience Experimental Medicine group to develop novel biomarkers that could define optimal treatment response as well as support patient stratification into clinical trials for drugs in development at Sosei Heptares

READ MORE...

Drug Discovery

Trends and Innovation in Drug Discovery at Sosei Heptares

By Matt Barnes, Lisa Stott, David Tippet | Jan 9, 2019

We recently attended the British Pharmacological Society’s Pharmacology 2018 meeting on December 18th – 20th in London where we made two presentations including: 1 – Oral presentation on our approach to studying GPCRs in immuno-oncology and 2 – Poster presentation detailing a technology evaluation examining binding assay techniques at the histamine H4 receptor.

READ MORE...

Development

Single and multiple dose safety, tolerability and pharmacokinetics of the selective M1 receptor partial agonist HTL0018318 in healthy volunteers

By Pradeep Nathan | Dec 18, 2018

We attended the American College of Neuropsychopharmacology meeting on December 9-13, 2018 in Florida, U.S., and presented on the safety, tolerability and pharmacokinetics of the selective M1 receptor partial agonist HTL0018318 in healthy volunteers.

READ MORE...

Drug Discovery

New small molecule HTL0014242 shows early promise for slowing neurodegeneration

By Kirstie Bennett | Dec 9, 2018

Researchers from the Sheffield Institute for Translational Neuroscience (SITraN) at the University of Sheffield, UK working with scientists at Sosei Heptares have presented findings from preclinical studies investigating a new small molecule HTL0014242 in preclinical models of the neurodegenerative condition motor neurone disease (MND).

READ MORE...

Corporate

Our Approach to Drug Discovery

By Sosei Heptares | Nov 28, 2018

An introduction to our unique and rationale approach to drug discovery which we hope will deliver new medicines for patients

READ MORE...

Corporate

Introduction to Sosei Heptares

By Sosei Heptares | Nov 27, 2018

Sosei Heptares is an international biopharmaceutical company focused on the design and development of new medicines originating from its proprietary GPCR-targeted StaR® technology and structure-based drug design platform capabilities.

READ MORE...

Platform Technology

Structure-Based Drug Discovery of G protein-coupled receptors (GPCRs)

By Kirstie Bennett | Aug 29, 2018

We attended the 15th Meeting of the Asian-Pacific Society for Neurochemistry, held in August 27-29, 2018 in Macau, China. The presentation was focussed around our candidate compound HTL0014242 – a negative allosteric modulator of the metabotropic glutamate 5 receptor (mGlu5). We presented the development of HTL0014242 from hit generation, using a fragment screening approach, to some preliminary efficacy data in the SOD1G93A mouse model of amyotrophic lateral sclerosis (also known as motor neurone disease); data generated through a Sosei Heptares-funded PhD student in Dr Richard Mead’s lab at the Sheffield Institute for Translational Neuroscience.

READ MORE...

Platform Technology

Manipulation of allosteric mechanisms in GPCR drug design

By Stacey Southall | Aug 3, 2018

We attended "Structure and Mechanism of Membrane Proteins", a Biochemical Society meeting on August 2-3, 2018 at Maple House in Birmingham UK, and presented recent case studies of allosteric modulators of GPCRs where Sosei Heptares StaR technology has enabled structural and biophysical characterisation of allosteric binding pockets and the mode of modulation on GPCRs. We explain how understanding of this diverse range of sites and mechanisms opens new avenues in SBDD towards generation of GPCR targeted drugs with improved therapeutic profile.

READ MORE...

Platform Technology

Beyond the Happy Water

By Ben Tehan | Apr 11, 2018

We presented our research on water molecules and recent advances in the quantification of their contributions at "Structure-Activity Relationships".

READ MORE...